Clinical trial · Observational
The IGF Axis Involvement in Immune Tumor Microenvironment in Ovarian Cancer and Its Clinical Significance
NCT03846856CI-TRIAL-00037944unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to evaluate the insulin-like growth factor (IGF) axis involvement in the immune tumor microenvironment in ovarian cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biopsy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Ovarian cancer patients
- description
- Biopsy will be taken from ovarian cancer patients and sent to laboratory for analysis
- interventionNames
- Other: Biopsy
Primary outcomes (1)
- measure
- Involvement of IGF Axis in Ovarian Cancer
- timeFrame
- Two years
- description
- Ovarian cancer specimens taken during surgical procedures will be evaluated and analyzed by flow cytometry assays to determine the involvement of the IGF axis in the immune tumor microenvironment in ovarian cancer
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Women diagnosed with epithelium ovarian cancer who have undergone surgery Exclusion Criteria: * Pregnant women
References
Publications (0)
Data not yet available
No reference posted for this study.